A prospective, randomized, phase II study of preoperative plus postoperative imatinib mesylate (Gleevec, formerly STI-571) in patients with primary, recurrent, or metastatic resectable, Kit-expressing, gastrointestinal stromal tumor (GIST).

Trial Profile

A prospective, randomized, phase II study of preoperative plus postoperative imatinib mesylate (Gleevec, formerly STI-571) in patients with primary, recurrent, or metastatic resectable, Kit-expressing, gastrointestinal stromal tumor (GIST).

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2011

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Planned end date changed from 1 Jul 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top